Where Peptide Work Actually Happens in Africa: Centres, Instruments and Access

Peptide work on this continent concentrates in a small number of shared analytical facilities attached to universities and national research institutes, and the people doing it book instrument time rather than own instruments. The scarce resource is not chemists and not bench space. It is a liquid chromatograph coupled to a mass spectrometer that is actually in service, an engineer who can reach it within days, and a consumables supply that does not take a quarter to arrive. Synthesis has been the tractable half since Merrifield anchored the growing chain to an insoluble support and turned a multi-step solution synthesis into a repetitive sequence of coupling and washing on a resin bead ^[1] — the change that made peptides cheap enough to make routinely, and the reason a modestly equipped department can attempt one at all. What that shift did, and what equipment catalogues never mention, is move the burden downstream — to purification, to identity confirmation, and to the documentation that makes either mean anything.

So the thing worth having is not a directory of laboratories. It is a map of instruments, of the service arrangements behind them, and of the terms on which someone outside the institution can put a sample on one. Those three change faster than any published list can track, and in most countries they are not published at all. What follows is the shape of that map and how to read it in your own country, rather than a pretence at being the map.

What a peptide bench actually requires, instrument by instrument

Separate the equipment that lets work happen from the equipment that decides whether the work was correct. Small-scale synthesis on solid support can be done in a fritted vessel on a shaker in a functioning fume hood; an automated synthesiser is a throughput convenience, not a gate. The gate sits downstream and is short: something that separates a crude mixture into a defined fraction, something that confirms the fraction is the sequence claimed for it, and something that isolates it as a dry solid. Everything else is negotiable. Those three are not — and the middle one is the most often over-read, because a mass match establishes composition rather than sequence.

The pattern in that table is the whole argument. The cheap items are widely held; the decisive ones are shared, because they are institutional objects rather than pieces of equipment. A mass spectrometer arrives with a gas supply, a service contract, a trained operator, a booking system and a queue, and it stops being an instrument the moment any one of those is withdrawn. Which is why asking which laboratory to join is usually the wrong opening question. The better one is which mass spectrometer in the country is currently under contract, and who controls the diary for it.

Where the capability is concentrated, and why the map looks like that

The documented anchors are few. The Holistic Drug Discovery and Development Centre at the University of Cape Town is the clearest published example of integrated small-molecule capability built and operated on the continent, and its own account is candid about the starting position: the initial disadvantages of doing the project in Africa revolved around limited access to drug discovery infrastructure, technology platforms and experience ^[2]. Read that as an inventory note rather than a complaint. Even the flagship had to assemble the platform layer before it could assume it.

Below the flagship level, the honest statement is that no continent-wide register of research instrument capability exists. The nearest quantitative proxy is accreditation, and it measures a different population. A survey of clinical laboratories identified 380 laboratories in sub-Saharan Africa accredited to international quality standards, 91 percent of them in South Africa, and found 37 of 49 countries with none at all ^[5]. That is medical testing rather than synthetic chemistry; the number should never be quoted as a count of chemistry facilities. What transfers is the distribution, because both populations rest on the same substrate — calibration services, resident engineers, procurement that can buy a consumable inside a quarter, and an institution willing to fund a quality system that produces no papers.

The resulting geography is a short list of national hubs — typically one or two universities or a national research institute per country holding the shared instruments for everyone else — plus a thin second layer of regional and international institutes funded for a specific disease or agricultural programme that own excellent analytical equipment as a side effect. That second layer is the most overlooked access route on the continent: the instruments are under contract because a funder requires it, and the spare capacity is real.

Booking instruments instead of buying them

The core-facility model — centralised instruments, a dedicated operator, per-sample charging, open to users outside the owning department — is how this work is done everywhere in the world, not an African improvisation. What differs here is queue length, consumable lead time, and how poorly the facilities are advertised. Very few appear in search results for the instruments they run. They are found institutionally, in a fairly reliable order.

• The national research council or science granting agency: it funded the large instruments and usually publishes what it funded and where it was installed.
• The research support or technology transfer office of the country's largest university — core facilities are listed under research services far more often than under a department.
• The national accreditation body's public directory of accredited laboratories, which lists each laboratory's scope of accredited methods and is the only routinely maintained public list of laboratory capability in most countries.
• The regional accreditation body where no national one exists: SADCAS, registered as a non-profit company under Botswana law in 2005 and approved as a SADC subsidiarity institution in 2007, accredits conformity assessment providers in the thirteen SADC member states that have no national accreditation body of their own ^[8].
• Institutes attached to a named disease or agricultural programme, whose analytical platforms were bought against a grant and are frequently under-booked.
• The pharmacy or veterinary faculty rather than the chemistry department — preparative chromatography and lyophilisers often live there.

What a facility asks for is predictable: an internal host, a submission form, hazard information for what you are sending, a purchase order, and a statement of what the material is. What you should ask them matters more — when the instrument was last serviced and by whom, where that engineer is based, whether columns, solvents and gases are in stock or on order, what the realistic turnaround is against the advertised one, and whether results come with raw data files or as a summary only. A facility that answers those five precisely is one worth building a plan around.

An instrument on an inventory is not an instrument in service

This variable breaks more plans than any other, and the largest published audit of it comes from hospital equipment rather than analytical chemistry. Across 112,040 pieces of medical equipment in sixteen countries, an average of 38.3 percent was out of service, the range across countries running from under 1 percent to 47 percent; the authors attributed the failures to lack of training, weak health technology management and infrastructure rather than to the equipment itself ^[3]. That figure is not a measurement of research instruments and must not be recycled as one. It measures the ecosystem those instruments sit inside — the same engineers, the same spare-parts import routes, the same maintenance budgets that get cut first.

Donation deserves separate attention, because a substantial share of African research equipment arrives that way and carries a distinctive failure pattern. WHO's guidance on medical device donations makes the operative point without hedging: a donation should be solicited and assessed with the same rigour normally applied to a purchase ^[4]. An instrument with no service contract, no engineer within reach, no consumable supply route and no documentation in a language anyone in the building reads is not capability — it is occupied floor space with a plaque on it. Whether a facility can run your sample is settled by three things unrelated to the make of the machine: gas supply, column supply, and whether anyone within a day's travel can replace an ion source.

What accreditation means here, and what it does not

Accreditation under ISO/IEC 17025 is granted against a scope, not against a building. A laboratory is accredited for a named list of methods on named matrices; work outside that list is unaccredited work performed in an accredited laboratory — legitimate, common, and needing only to be described accurately. A scope entry covering chromatographic assay of a particular class of analyte tells you the quality system, calibration traceability and competence records were audited for that method. It tells you nothing about a method the auditors never examined. Reading the scope rather than the certificate is the difference between what a facility can defend and what it advertises.

The African medical laboratory system reached international standards by a deliberately stepwise route, and the reasoning behind it travels well beyond clinical testing. WHO's African region introduced a stepwise accreditation process specifically because few countries in the region had quality standards that were affordable to implement and practical to monitor, which put full international accreditation out of reach for most laboratories ^[6]. The implementation record gives the scale: by March 2015, 27 of 47 member states had appointed a focal point, 98 auditors from 17 African countries had been certified, and 159 laboratories were audited between May 2013 and March 2015, with a mean compliance score of 69 percent — 70 percent reaching two stars or better and 1 percent reaching five ^[7]. Medical laboratories again, not chemistry facilities. The transferable finding is the ladder itself: a facility part-way up a recognised improvement scheme, with documented internal audits, is a more dependable collaborator than one with an impressive instrument and no quality system behind it.

If there is no centre in your country

Four routes exist, each with a failure mode worth naming in advance rather than discovering. The first is affiliation: visiting researcher status, an honorary appointment or a written memorandum with an institution that already owns the instruments. Its failure mode is administrative, and the fix is to have access terms, charging basis and data ownership written down before any sample moves.

The second is sending samples to a regional facility and keeping the work where you are. Its failure mode is custody: an unbroken record of who held the material and under what conditions, from your bench to theirs, without which the result is uninterpretable however good the instrument was. The third is commercial contract analysis — fast and predictable, and its failure mode is receiving a number rather than the data behind it; a purity percentage reported without its chromatogram is the standard case, which is why data release is a question to settle at quotation stage. The fourth is the least fashionable and most often correct: narrow the work to what can be verified with the instruments genuinely available, and record the limit in the method. A stated capability limit is a professional position; an unstated one is a finding waiting to be made by somebody else.

What is not documented

Everything cited above is survey or administrative data about facilities and equipment. None of it is experimental data about materials, and none comes from a study designed to answer the question this article asks. There is no published instrument census for African research laboratories — no register of chromatographs or spectrometers by country, service status or spare capacity. The accreditation counts describe clinical testing ^[5][7], the equipment audit describes hospital devices ^[3], and the one detailed account of building integrated capability describes a single centre in a single therapeutic area ^[2]. Extrapolating from any of them to a national chemistry capability is inference, and should be labelled as inference when written down.

Two gaps matter for planning. Nobody publishes instrument uptime for African core facilities, so real availability can only be established by asking current users rather than reading a website. And nobody tracks consumable lead times, which govern throughput more tightly than instrument time does: a booked slot is worthless if the column for it is three months away. Both are answerable by one call to a facility manager and unanswerable by any amount of desk research — an unsatisfying conclusion, and an accurate one.